Chemoimmunotherapy (CIT) has been the long-standing cornerstone of the first line treatment for patients with chronic lymphocytic leukaemia (CLL). More recently, however, continuous treatment with Bruton’s tyrosine kinase inhibitors (BTKis) emerged as a new standard of care frontline treatment for the majority of CLL patients. However, the continuous nature of this treatment modality is associated with a considerable treatment burden, long-term toxicity and potential clonal selection. Therefore, research efforts have focused on the development of new, time-limited and chemotherapy-free first line treatment regimens for patients with CLL.1 In this mini review, the main clinical trial results with these different fixed-duration regimens are summarised.
